Pressure Bio's Q2 Revenues Up 49 Percent on PCT Sales Jump | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Pressure BioSciences today said that its second-quarter revenues rose 49 percent year over year as sales connected to its flagship technology increased 78 percent.

During the three months ended June 30, the South Easton, Mass.-based sample prep instrument firm posted revenues of $402,104, compared to $270,381 for Q2 2009. Sales of its pressure cycling technology, or PCT, instruments, and related products and services rose to $283,382 from $159,202 in Q2 2009.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.

Mar
02
Sponsored by
VelaDx

This online seminar will highlight recent advances in the use of next-generation sequencing to detect drug-resistant mutations in patients with HIV or HCV. 

Mar
09
Sponsored by
Bio-Rad

This webinar will discuss how next-generation sequencing and digital PCR can be used in a complementary manner for liquid biopsies in order to improve patient care.